Repurposed drugs can be powerful in cancer care — but only when they’re matched to the right biology.
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how deep multi-omics testing (DNA, RNA, immune, and spatial biology) reveals whether agents like ivermectin, methylene blue, mebendazole, or fenbendazole actually fit your tumor’s molecular targets.
Many “alternative” treatments fail because they’re given blindly. Precision oncology replaces that guesswork by combining repurposed drugs, on-label therapies, and immunotherapy support into one guided plan designed for your unique cancer. Dr. Prato shows how these strategies are used at Envita to enhance drug delivery, minimize toxicity, and strengthen immune response.
🎯 What You’ll Learn in This Episode:

• Why repurposed drugs can help — but fail without precision targeting

• How DNA, RNA, and immune/spatial mapping identify the right off-label options

• When microdosing, compounding, or direct tumor delivery may improve results

• Why published studies are a starting point — not a one-size-fits-all guide

• How combining on-label and off-label medications improves outcomes safely

• Why Envita’s precision oncology achieved better responses and fewer side effects
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“Repurposed doesn’t mean random — it means targeted, tested, and personalized.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493